BioSpace News Archive

Senju Pharmaceutical Co., Ltd. and Novaliq GmbH are pleased to announce the closing of a license agreement on Japan rights to develop, manufacture, and commercialize NOV03, the first and only prescription treatment for signs and symptoms of dry eye disease that directly targets tear evaporation.

BioInvent International Abstract for the ongoing clinical trial with BI-1206 in combination with rituximab has been accepted to the ICML and showcases the study design and status, and summarizes the early clinical results generated so far in the dose escalation phase.

Spago Nanomedical Spago Nanomedical AB announced the establishment of a Scientific Advisory Board comprised of scientific and clinical leaders in oncology and nuclear medicine.

Valo Therapeutics Oy, the developer of novel, adaptable immunotherapies for cancer, announces a collaboration with global contract research organization, Texcell, to investigate immune responses to PeptiCRAd-1 in its Phase 1 clinical study.

Seagen Inc. announced updated efficacy and safety results from Part C of a phase 2 single-arm trial evaluating the antibody-drug conjugate ADCETRIS® in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine for the frontline treatment of patients with early-stage classical Hodgkin lymphoma.

Senju Pharmaceutical Co., Ltd. and Novaliq GmbH are pleased to announce the closing of a license agreement on Japan rights to develop, manufacture, and commercialize NOV03, the first and only prescription treatment for signs and symptoms of dry eye disease that directly targets tear evaporation.

The Danish biotech company, Tetra Pharm Technologies, announces promising results from preclinical testing of its pain-relieving drug - TPT0301.

AlzeCure Pharma AB announced that a new scientific article on preclinical results supporting a disease-modifying effect with NeuroRestore ACD856 has been made available online.

Charles River Laboratories International, Inc. announced the launch of its off-the-shelf lentiviral vector packaging plasmids, providing a streamlined solution to the challenges associated with plasmid sourcing in cell and gene therapies.

eGenesis, a biotechnology company developing human-compatible organs for the treatment of organ failure, announced the publication of a paper in the journal Nature Communications highlighting novel findings from the largest cohort of long-term non-human primate recipients of porcine kidney xenotransplantation to date.